İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Published on by Academic Awards

Assist. Prof. Dr. İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Bitlis Eren University | Turkey

Assist. Prof. Dr. İlhan Sabancılar is a biochemist and medical researcher at Bitlis Eren University, Turkey, whose work bridges biochemistry, molecular medicine, and pharmaceutical sciences. His research primarily focuses on the anticancer, antioxidant, antimicrobial, and anti-inflammatory properties of bioactive compounds, natural extracts, and nanomaterials. Assist. Prof. Dr. İlhan Sabancılar has contributed to the synthesis and biological evaluation of novel heterocyclic and aza-acyclic nucleoside derivatives, investigating their potential as therapeutic agents through molecular docking and cytotoxicity studies. His publications in journals such as Pharmaceuticals, Current Issues in Molecular Biology, and Reviews on Environmental Health reflect his expertise in oxidative stress, trace element biochemistry, and drug development. With 9 publications and 247 citations, he has established a growing scientific presence supported by multiple research projects on oxidative stress, viral inhibition, and cancer therapeutics. A member of the Turkish Biochemical Society and the Molecular Cancer Research Association, Assist. Prof. Dr. İlhan Sabancılar’s multidisciplinary approach and consistent research output position him as a promising scholar contributing significantly to the advancement of biomedical and biochemical sciences.

Profile: Scopus | Orcid | Google Scholar

Featured Publications

1. Unsal, V., Cicek, M., & Sabancilar, İ. (2021). Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Reviews on Environmental Health, 36(2), 279–295.

2. Bilden, A., Sabancılar, İ., Yalçın Azarkan, S., Karadağlı, K., Kaya, S., Kahraman, M., & Çiçek, M. (2025). Investigating the therapeutic potential of crude leech saliva based on its anticancer, antioxidant, and anti-inflammatory effects. Current Issues in Molecular Biology, 47(5), 328.

3. Sabancilar, İ., Unsal, V., Demir, F., Toprak, G., & Pekkolay, Z. (2023). Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Medica, 65(1), 46–52.

4. Alhilal, M., Alhilal, S., Gomha, S. M., Farag, B., Sabancilar, İ., & Ouf, S. A. (2025). Biological evaluation and molecular docking studies of novel aza-acyclic nucleosides as putative antimicrobial, anticancer, and antioxidant agents. BMC Chemistry, 19(1), 255.

5. Muhammed Ayral, H. T., Toprak, S. F., Dedeoğlu, S., & Sabancılar, İ. (2021). Kronik Otitis Media’da Tiyol-Disülfid Homeostazının Değişikliği. Dicle Tıp Dergisi, 48(1), 197–204.

6. Toprak, G., Sabancılar, İ., Özcan, N., & Alkan, H. (2020). Total oxidant status (TOS), total antioxidant status (TAS), ferritin and vitamin D levels in patients with chronic hepatitis C. Microbiology and Infectious Diseases, 4(2), 1–4.

 

Cheng Yi | Oncology | Best Researcher Award

Published on by Academic Awards

Mr. Cheng Yi | Oncology | Best Researcher Award

West China Hospital of Sichuan University | China

Mr. Cheng Yi, a distinguished Medical Doctor from Sichuan, currently serves as a professor and doctoral supervisor at the Cancer Center of West China Hospital, Sichuan University, and as an adjunct doctoral supervisor at Chengdu University of Traditional Chinese Medicine. He earned his Bachelor and Master of Medicine from Xi’an Jiaotong University, his Doctor of Medicine from Fudan University, and completed postdoctoral research at the University of Toronto. Since 1996, he has been deeply engaged in oncology clinical practice, scientific research, and teaching, advancing to professor and chief physician in 2006. His academic roles include standing committee and deputy director positions across multiple Chinese medical associations, reflecting his leadership in oncology and integrative medicine. With 138 publications, over 2,422 citations, and an h-index of 26, his research spans nanomedicine, cancer therapeutics, molecular oncology, immunotherapy, and systematic reviews, with impactful studies published in Journal of Materials Chemistry B, Nano Research, Frontiers in Oncology, PLoS One, and Journal of Cancer Research and Clinical Oncology. His international experience and consistent contributions to cancer treatment innovation highlight his strong candidacy for the Best Researcher Award, showcasing excellence in scientific impact, academic mentorship, and translational oncology research.

Profile: Scopus | Orcid

Featured Publications

Zhang, L.-N., Wei, Y.-F., Ran, X.-Y., Shi, L., Wang, Z.-Y., Chen, S.-Y., Yi, C., Yu, X.-Q., & Li, K. (2025). Liberating exciton transfer as a pioneering strategy to construct type I photosensitizers for hypoxia deep-seated metastases suppression. JACS Au. Advance online publication.

Tan, S., Feng, M., Zhou, N., Zhang, S., Yi, C., & Gou, H. (2025). DNA damage response and repair gene mutations predict clinical outcomes in biliary tract cancer. Cancer. Advance online publication.

Chen, P., Hou, W., Li, C., Liang, Q., Ma, L., Zhao, X., & Yi, C. (2025). Lived experiences of patients with advanced pancreatic cancer on patient-reported outcomes (PROs) management: A qualitative phenomenological study in Southwest China. BMJ Open, 15(1), e084259.

Ran, X.-Y., Xia, W.-L., Zhang, L.-N., Yu, X.-Q., Chen, P., Xie, K.-P., Zhao, Y., Yi, C., & Li, K. (2024). De novo design of type-I photosensitizer agents based on structure-inherent low triplet energy for hypoxia photodynamic therapy. Materials Horizons. Advance online publication.

Tan, S., Zhang, S., Zhou, N., Cai, X., Yi, C., & Gou, H. (2023). Efficacy and safety of fruquintinib dose-escalation strategy for elderly patients with refractory metastatic colorectal cancer: A single-arm, multicenter, phase II study. Cancer Medicine, 13(1), e6786.

Wei, Y., Zheng, L., Yang, X., Luo, Y., Yi, C., & Gou, H. (2023). Identification of immune subtypes and candidate mRNA vaccine antigens in small cell lung cancer. The Oncologist, 28(11), oyad193.